Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

XORTX Therapeutics Inc.

  • Public · NASDAQ: XRTX
  • 3 employees
$3.8MMarket cap
3Employees
XRTXNASDAQ
2018IPO

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$3.8M
NASDAQ: XRTX

15-minute delayed · data by Polygon.io

Market cap
$3.8M
Open
Day range
Prev close
Volume
IPO date
May 4, 2018

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review XORTX Therapeutics Inc..

Write a review
Explore

Similar companies

Browse all →